T cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory receptor expressed
on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer …

Programmed death-ligand 1 [PD-(L) 1], cytotoxic T-lymphocyte associated protein 4 (CTLA-
4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer …

Dual blockade of the PD-1 and TIGIT coinhibitory receptors on T cells shows promising early
results in cancer patients. Here, we studied the mechanisms whereby PD-1 and/or TIGIT …

Primary brain tumors, such as glioblastoma (GBM), are remarkably resistant to
immunotherapy, even though pre-clinical models suggest effectiveness. To understand this …

CD8+ T cells within the tumor microenvironment (TME) are exposed to various signals that
ultimately determine functional outcomes. Here, we examined the role of the co-activating …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a
dismal prognosis. While immunotherapy has been deemed a breakthrough treatment for …

Tumors escape immune surveillance by inducing various immunosuppressive pathways,
including the activation of inhibitory receptors on tumor-infiltrating T cells. While monoclonal …

Several preclinical studies demonstrate that antitumor efficacy of programmed cell death-1
(PD-1)/programmed death-ligand 1 (PD-L1) blockade can be improved by combination with …

The activating receptor CD226 is expressed on lymphocytes, monocytes, and platelets and
promotes anti-tumor immunity in pre-clinical models. Here, we examined the role of CD226 …

Purpose: Adding losartan (LOS) to FOLFIRINOX (FFX) chemotherapy followed by
chemoradiation (CRT) resulted in 61% R0 surgical resection in our phase II trial in patients …